Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 12.17% is 27% below its 5-year average of 16.76%, around the middle of its 5-year range (4.25%–25.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.67% below its 12-month average of 13.94%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.17%.
DEBT TO ASSETS RATIO
12.17%
DEBT TO ASSETS RATIO AVG TTM
13.94%
DEBT TO ASSETS RATIO AVG 3Y
17.84%
DEBT TO ASSETS RATIO AVG 5Y
16.76%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-12.67%
CURRENT VS 3Y AVG
-31.78%
CURRENT VS 5Y AVG
-27.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+13425.49%
vs the sector median at left
Personalis, Inc.
Market Cap
$1.71B
Debt to Assets Ratio
12.17%
TTM Avg
13.94%
3Y Avg
17.84%
5Y Avg
16.76%
Market Cap
$1.71B
Debt to Assets Ratio
0.44%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.72B
Debt to Assets Ratio
0.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.69B
Debt to Assets Ratio
0.56%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.74B
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Debt to Assets Ratio
0.70%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.77B
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.63B
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.63B
Debt to Assets Ratio
0.76%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Personalis, Inc. (PSNL) | $1.71B | 12.17% | 13.94% | 17.84% | 16.76% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 0.44% | N/A | N/A | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.72B | 0.26% | N/A | N/A | N/A |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.69B | 0.56% | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | 0.09% | N/A | N/A | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.75B | 0.70% | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | 0.50% | N/A | N/A | N/A |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.63B | 0.12% | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.63B | 0.76% | N/A | N/A | N/A |
| Novocure Ltd (NVCR)vs › | $1.78B | 0.29% | N/A | N/A | N/A |
Debt/Assets
12.2%
Debt/Equity
0.16
Current Ratio
5.28
Interest Coverage
-429.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 12.17% |
| 2026-03-31 | 11.92% |
| 2025-12-31 | 11.95% |
| 2025-09-30 | 17.24% |
| 2025-06-30 | 16.41% |
| 2025-03-31 | 16.25% |
| 2024-12-31 | 16.37% |
| 2024-09-30 | 18.82% |
| 2024-06-30 | 25.15% |
| 2024-03-31 | 24.02% |
| 2023-12-31 | 21.20% |
| 2023-09-30 | 20.86% |
| 2023-06-30 | 19.59% |
| 2023-03-31 | 18.18% |
| 2022-12-31 | 16.62% |
| 2022-09-30 | 15.36% |
| 2022-06-30 | 16.26% |
| 2022-03-31 | 15.78% |
| 2021-12-31 | 14.71% |
| 2021-09-30 | 14.72% |
| 2021-06-30 | 4.25% |
| 2021-03-31 | 2.69% |
| 2020-12-31 | 4.49% |
| 2020-09-30 | 4.50% |
| 2020-06-30 | 7.79% |
| 2020-03-31 | 0.73% |
| 2019-12-31 | 1.27% |
| 2019-09-30 | 0.89% |
| 2019-06-30 | 10.46% |
| 2019-03-31 | 32.85% |
| 2018-12-31 | 11.99% |
